Expression of PRLHR in patients with low-grade gliomas (WHO I-II) is higher than that in patients with high-grade gliomas (WHO III-IV), including GBM, suggesting that the prognosis of patients with high-grade gliomas is worse (Figures 7H, K and Supplementary Data 3, 4). The gene discussed is PRLHR; the disease is central nervous system cancer.